About the Conference
General Information
Scientific Program Committee
Program
Search Program and Abstracts
Schedule-at-a-Glance
Contact Us
View Webcasts
View Posters

 

 

 

 

 

 


 
 Program
Sunday
February 24, 2002
5–7 pm
 
Time/Day Monday
February 25, 2002 		Tuesday
February 26, 2002		 Wednesday
February 27, 2002		 Thursday
February 28, 2002
8:30-9 am
Plenary Lecture
2.   Dendritic Cell Responses
and Host Interactions

11. Analysis of HIV-1 Envelope Glycoproteins and Neutralizing Antibodies
22.   New Insights into
Mechanisms of HIV-1
Resistance to Reverse Transcriptase Inhibitors
32.   HIV-1 Virion Morphogenesis
9-9:30 am
Plenary Lecture
3.   Immune Reconstitution and Immunologic Responses
to HAART
12.   A Potential HIV-1 Vaccine Using a Replication Defective Adenoviral Vaccine Vector
23.   Treatment of Patients
with Drug Resistant
Virus
33.   Transmission and
Propagation of SIV and HIV Infection in vivo
10 am-12:30 pm

Oral Abstract Sessions

4.   Antiretroviral Chemotherapy: New Agents
5.   Epidemiology and Infection Control
6.   Immunopathogenesis of HIV and SIV Infections
7. Opportunistic Infections and Complications of Antiretroviral Therapy
13. Antiretroviral Chemotherapy: Combination Therapy, Drug Resistance, and Treatment Interruption
14. Molecular Virology
15. Neuropathogenesis
16. Active and Passive Immunization Studies
24.   Antiretroviral Chemotherapy/Pathogenesis of Primary HIV Infection
25. Immunology
26. Pediatric/Maternal-Fetal HIV Infection and Issues in HIV-Infected Women
27. Hepatitis B and C Co-Infection
28. Pharmacokinetics and Therapeutic Drug Monitoring
 9:30–11:45 am
34.   Late Breakers II
2-4 pm

Symposia
8. Host-Virus Interactions
17. T-Cell Turnover and
Thymic Function
29. Viral Pathogenesis
 
9. Tuberculosis/HIV
Co-Infection
18. HIV and Hepatitis: Co-Morbidity and Therapy
30. The Promise and
Challenge of Antiretroviral Therapy in Developing Countries  

2-4 pm
Oral Abstract Sessions

10.   Late Breakers I
19.   Envelope, Receptors, and Entry
4:30-6:30 pm

Poster Sessions
35.   HIV and SIV Diversity
36.   Vpr
37.   Molecular Virology
38.   Viral and Cellular Proteins on the Virion Surface
39.   Envelope-Receptor Interactions
40.   Chemokines and Chemokine Receptors
41.   CD4 T-Helper Responses to HIV
42.   CD8+ T-Cell Responses and Influences of CD4+ T Cells
43.   Neutralizing Antibodies
44.   DC-SIGN and Dendritic Cells
45.   Exposed Uninfected Individuals
46.   Immunology: Miscellaneous
47.   DNA Vaccines
48.   Protein and Inactivated Virus Vaccines
49.   Vaccine-Related Studies
50.   Therapeutic Vaccine Studies
51.   Impact of Host Genetics on Viral Transmission and Disease Progression
52.   Pathogenesis Studies in Animal Models
53.   Pathogenesis: Miscellaneous
54.   Pathogenesis of Acute HIV Infection
55.   Diagnosis and Treatment of Primary Infection
56.   Acute Infection: Resistance, Fitness, and Transmission
57.   Novel Antiretroviral Chemotherapeutic Agents
58.   Entry Inhibitors
59.   Targeting the Viral Reservoir
60.   Antiretroviral Chemotherapy in Drug Naïve Patients
61.   Antiretroviral Chemotherapy in Previously Treated Individuals
62.   Pharmacokinetics of Antiretroviral Drugs
63.   Drug-Drug Interactions
64.   Therapeutic Drug Monitoring
65.   Antiretroviral Chemotherapy in Resource Limited Settings
66.   Antiretroviral Chemotherapy: Predictors of Sucessful Outcome
67.   Disease Progression/Effects of Treatment
68.   Immune Reconstitution with Antiretroviral Chemotherapy
69.   Immunopathogenesis Issues Addressed by Therapeutic Interventions
70.   Thymic Function and Immune Reconstitution
71.   IL-2 and Other Forms of Immunotherapy
72.   Treatment Interruption
73.   Adherence to Therapy
74.   Antiretroviral Chemotherapy: Miscellaneous Topics
75.   Resistance to Antiretroviral Chemotherapeutic Agents
76.   HIV Resistance and Fitness
77.   Resistance Testing in Drug Selection
78.   Diagnostic Techniques: Viral Sequencing Technologies
79.   Diagnostic Techniques: Assays for Serologic Diagnosis and Viral Quantitation
80.   Viral, Fungal, and Protozoal Opportunistic Infections
81.   HHV-8, Kaposi's Sarcoma, and HIV-Related Lymphoma
82.   Tuberculosis and Other Mycobacterial Infections
83.   Discontinuation of Prophylaxis/Risk of Opportunistic Infections
84.   HCV Co-Infection and HIV/HCV Immune Responses
85.   HCV Co-Infection: Diagnosis and Pathogenesis
86.   HCV Co-Infection: Treatment
87.   Hepatitis Virueses: Influence on Morbidity, Mortality, and Response to Antiretroviral Therapy
88.   GBV-C Co-Infection
89.   HBV Co-Infection
90.   Incidence, Prevalence, and Pathogenic Correlates of Insulin Resistance and Lipodystrophy Syndrome
91.   Cardiovascular Disease Risk
92.   Switch Studies/Treatment of Lipodystrophy Syndromes
93.   Mitochondrial Toxicity/Hyperlactatemia
94.   Osteopenia/Osteoporosis
95.   Organ Specific Toxicities/Complications
96.   HIV-Associated Encephalopathy
97.   Neuropathogenesis
98.   Neuropathogenesis: Effects of Therapy
99.   Predictors and Causes of Mortality in HIV Disease
100. Molecular Epidemiology
101. HIV Incidence and Transmission
102. Effect of Gender/Sex on Viral Load, Pharmacokinetics and Responses to Antiretroviral Therapy
103. Cervico-Vaginal HIV Shedding: Immunologic and Virologic Correlates and Microbicides
104. Perinatal Transmission
105. Pediatric HIV Infection: Disease Progression and Responses to Therapy
106. Pediatric Opportunistic Infections
7-9 pm
Special Symposium 		 
21. Controversies in Antiretroviral Therapy